Skip to main content
. 2012 Dec 19;7(12):e51681. doi: 10.1371/journal.pone.0051681

Figure 2. Kinetics of CD3+, FOXP3+, ratio FOXP3+/CD3+ and CD20+ cells by immunohistochemistry in responding patients.

Figure 2

Median CD20+ cells were significantly different between cases treated with antibioticis and those treated with fludarabine or bendamustine with or without Rituximab at first response evaluation (p = 0.001) but not later during follow-up.